Kamada KMDA
NASDAQ KMDA
$8.04 +0.15 (+1.90%)
At close: Aug 20, 2026 · 12:44 PM UTC

Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026)

Kamada's (KMDA) quarterly Total Non-Current Liabilities came in at $63.9 million in Q1 2026, down 3.39% YoY from $66.1 million in Q1 2025, and up 2.59% on a QoQ basis from $62.2 million in Q4 2025.

Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Kamada (KMDA) has 13 years of Total Non-Current Liabilities data on file, last reported at $63.9 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 3.39% year-over-year to $63.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.9 million (down 3.39% YoY) and the FY2025 annual result came in at $62.2 million, down 1.82% from the prior year.
  • Total Non-Current Liabilities grew to $63.9 million in Q1 2026, from $62.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $85.7 million in Q1 2022 to a low of -$8.1 million in Q4 2024.
  • A 5-year average of $50.8 million and a median of $62.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 78674.89% — and 2024, when it plunged 439.82%.
  • Tracing KMDA's Total Non-Current Liabilities over 5 years: stood at $70.7 million in 2022, then sank by 96.63% to $2.4 million in 2023, then sank by 439.82% to -$8.1 million in 2024, then surged by 870.28% to $62.2 million in 2025, then gained by 2.59% to $63.9 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $63.9 million (Q1 2026), $62.2 million (Q4 2025), and $64.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 43.98 Bn 43.02 Bn - -13.28 Bn
2 Teva Pharmaceutical Industries 43.28 Bn 39.62 Bn 2.15 Bn 16.45 Bn
3 Zoetis 31.79 Bn 30.11 Bn 1.05 Bn 11.64 Bn
4 Takeda Pharmaceutical 28.69 Bn 22.89 Bn 5.10 Bn 33.50 Bn
5 United Therapeutics 22.25 Bn 19.58 Bn 683.80 Mn 607.80 Mn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn 18.76 Bn
7 Neurocrine Biosciences 15.58 Bn 15.19 Bn 935.80 Mn 1.37 Bn
8 Elanco Animal Health 11.87 Bn 11.34 Bn 798.00 Mn 6.42 Bn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - 334.00 Mn
10 Kamada 463.48 Mn 434.00 Mn 22.47 Mn 64.45 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 64.45 Mn
Mar 31, 2026 63.86 Mn
Dec 31, 2025 62.25 Mn
Sep 30, 2025 64.14 Mn
Jun 30, 2025 62.45 Mn
Mar 31, 2025 66.10 Mn
Dec 31, 2024 -8.08 Mn
Sep 30, 2024 61.94 Mn
Jun 30, 2024 58.99 Mn
Mar 31, 2024 59.49 Mn
Dec 31, 2023 2.38 Mn
Sep 30, 2023 61.39 Mn
Jun 30, 2023 71.81 Mn
Mar 31, 2023 -1.76 Mn
Dec 31, 2022 70.65 Mn
Sep 30, 2022 77,936.00
Jun 30, 2022 82.88 Mn
Mar 31, 2022 85.72 Mn
Dec 31, 2021 87.79 Mn
Sep 30, 2021 8.33 Mn